Journal: Frontiers in Cell and Developmental Biology

Article Title: Lysophosphatidic acid promotes endometrial decidualization in recurrent implantation failure patients by regulating LPAR6

doi: 10.3389/fcell.2025.1652740

Figure Lengend Snippet: Inhibition of LPAR6, but not LPAR1, attenuates decidualization of hESCs. (A) RT-qPCR showing relative IGFBP1 mRNA level in hESCs during decidualization after adding LPAR1 antagonists, AM095 or Ki16425. (B) RT-qPCR showing relative PRL mRNA level in hESCs during decidualization after adding LPAR1 antagonists, AM095 or Ki16425. (C) ELISA showing relative PRL protein level in hESCs during decidualization after adding LPAR1 antagonists, AM095 or Ki16425. (D) Immunofluorescence showing changes in cytoskeletal morphology in hESCs during decidualization after adding LPAR1 antagonists, AM095 or Ki16425. (E) The efficiency of LPAR6 knockdown by siLPAR6-2/3 detected with RT-qPCR. (F) RT-qPCR showing relative IGFBP1 mRNA level in hESCs during decidualization after adding siLPAR6. (G) RT-qPCR showing relative PRL mRNA level in hESCs during decidualization after adding siLPAR6. (H) ELISA showing relative PRL protein level in hESCs during decidualization after adding siLPAR6. (I) Immunofluorescence showing changes in cytoskeletal morphology in hESCs during decidualization after adding siLPAR6. (J) CCK-8 assay showing the effect of LPAR1 antagonists or siLPAR6 on cell proliferation. Error bars represent SEM, and the data are means of at least three independent experiments. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05; ns, not significant.

Article Snippet: After adhesion, the original medium was removed from the well, cells were transfected with siRNAs using Lipofectamine 3000 as mentioned before or treated with the following reagents: oleoyl-LPA, AM095 (4'-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-biphenyl-4-yl-Na, MCE, HY-16040), and Ki16425 (3-(4-[4-([1-(2-chlorophenyl)ethoxy]carbonyl amino)-3-methyl-5-isoxazolyl] benzylsulfanyl) propanoic acid, Selleck #S1315) and incubated at 37 °C for 24 h. Lastly, CCK-8 reagent was added, the plates were incubated at RT for 20 min, and the absorbance at 450 nm was measured using a plate-reader.

Techniques: Inhibition, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay, Immunofluorescence, Knockdown, CCK-8 Assay

Journal: Scientific Reports

Article Title: Compound 48/80 increases bladder compliance by activating MMP-2 and inhibiting TIMP-2

doi: 10.1038/s41598-025-05521-z

Figure Lengend Snippet: The MMP-2 inhibitor ARP100 blocks the increase in mechanical compliance driven by compound 48/80. ( A ) Representative pressure-volume trace of ex vivo filling of C57Bl/6 mouse bladders in presence of the selective MMP-2 inhibitor ARP100 (200 nM) alone and after addition of the Mrgprb2 receptor agonist compound 48/80 (10 µg/mL). ARP100 blocks the increase in compliance caused by compound 48/80, signified by the absence of rightward shift of stress-stretch curve ( B ) and no significant increase in stretch at 5, 10, and 25 mmHg ( C , P = 0.093). Stiffness remains unchanged in both groups ( D ). N = 6.

Article Snippet: ARP100 (2-[((1,1’-Biphenyl)−4-ylsulfonyl)-(1-methylethoxy)amino]- N -hydroxyacetamide) was obtained from Tocris (Bristol, UK).

Techniques: Ex Vivo

Journal: Scientific Reports

Article Title: Compound 48/80 increases bladder compliance by activating MMP-2 and inhibiting TIMP-2

doi: 10.1038/s41598-025-05521-z

Figure Lengend Snippet: Compound 48/80 increases in the amplitude and leading slope of transient pressure events independent of MMP inhibition. ( A) Representative traces of transient pressure events in presence of the MMP inhibitor doxycycline alone and after addition of the Mrgprb2 receptor agonist compound 48/80 (10 µg/mL). The increase in peak amplitude ( B ) and leading slope ( C ) were unaffected by doxycycline ( P = 0.0002 for peak amplitude and P = 0.003 for leading slope). ( D–F) The selective MMP-2 inhibitor ARP100 also had no effect ( P = 0.010 for peak amplitude and P = 0.0004 for leading slope). * P ≤ 0.05. ** P ≤ 0.01. N = 6.

Article Snippet: ARP100 (2-[((1,1’-Biphenyl)−4-ylsulfonyl)-(1-methylethoxy)amino]- N -hydroxyacetamide) was obtained from Tocris (Bristol, UK).

Techniques: Inhibition